Freye E, Levy J V
Klinik für Gefässchirurgie und Nierentransplantation Heinrich-Heine-Universität Düsseldorf.
Anasthesiol Intensivmed Notfallmed Schmerzther. 2004 Sep;39(9):527-37. doi: 10.1055/s-2004-825883.
Perioperative management of geriatric patients is becoming an important component in anaesthetic practice in the 21st century. This phenomenon is due to the fact that people aged 65 and over are the segment with the fastest growing population. Thus, it is estimated that by the year 2025 20 % of the population in the western hemisphere will be > 65 years of age. Currently, elderly patients comprise one-third of all operations, and one out of two patients older than 65 years of age will undergo an operation in their lifetime. The dramatic change in demographics of surgical patients will have a tremendous impact on the use of anaesthetics. Older patients facing surgery can generally be expected to be a more complex case than their younger counterparts. They have more systemic diseases (e. g. cardiac, pulmonary, endocrine), and usually these diseases have advanced to more serious stages. These patients may suffer disability, both physical and mental, and may show differences in the pharmacokinetic as well as the pharmacodynamic of compounds such as opioids. While neuronal numbers, dendrites and synapses decline with age and the ventricular volume triples, cerebral circulation is similar to young adults, although there is a reduction in cerebral blood flow (CBF). This is because of the lower unit weight, lower CBF and CMRO (2), which are tightly coupled in aging where autoregulation is preserved. However, because of a decline in dopaminergic, serotonergic, cholinergic and GABAergic transmitters, anticholinergic compounds (atropine, scopolamine) as well as some anaesthetics such as ketamine, benzodiazepines or even propofol may produce delirium and/or an increase in efficacy when given together with opioids. Therefore it is mandatory to consider a pharmacologic interaction with a potentiation and/or an addition in effects of other drugs when judging the net action of opioids in the elderly. Physicians and nurses treating geriatric patients tend to have an unfounded level of fear of complications associated with treating perioperative pain. Although it is known that inadequate analgesia may delay recovery, the treatment of perioperative pain in the geriatric patient remains inadequate, even relative to younger patients. It is well established that there is increased responsiveness to the effects of opioids in the elderly. This may result in an increased risk of respiratory depression, while especially the elderly female patient demonstrates an increase in the duration of effects, but the risk of nausea is not augmented. Increased sensitivity of older patients to systemic opioids mostly involves pharmacokinetic factors such as a higher proportion of unbound and active substances as well as changes in drug redistribution. Because of a 40 % reduction in stroke volume in the elderly, there is a protracted redistribution of opioids to the liver. This results in a prolonged metabolisation, a lesser inactivation over time followed by an increase in duration of effects, mainly impairment of respiration. To a much lesser extent, pharmacodynamic factors with an increased response at opioid receptor sites have to be considered. Although the mechanisms causing differences of opioid action in the elderly may be complex, the clinical implications are not. They include slow titration of opioids to allow for long circulation times, lower total doses because of increased sensitivity, and anticipation of a longer duration of action because of reduced clearance. Since elderly patients present multimorbidity, therapy of chronic pain has to be considered in the light of multidrug intake, which, due to interaction, results in marked side-effects, and a prolonged duration of action. Those opioids should be used which, due to their pharmacokinetic properties, have a reduced volume of distribution, present a low plasma protein binding and finally result in the formation of no pharmacologically active metabolites.
老年患者的围手术期管理正成为21世纪麻醉实践中的一个重要组成部分。这一现象是由于65岁及以上人群是人口增长最快的部分。因此,据估计,到2025年,西半球20%的人口将超过65岁。目前,老年患者占所有手术的三分之一,65岁以上的患者中有二分之一在其一生中会接受手术。外科患者人口统计学的巨大变化将对麻醉的使用产生巨大影响。一般来说,面临手术的老年患者比年轻患者的情况更复杂。他们有更多的全身性疾病(如心脏、肺部、内分泌疾病),而且通常这些疾病已发展到更严重的阶段。这些患者可能会出现身体和精神上的残疾,并且在阿片类药物等化合物的药代动力学和药效学方面可能表现出差异。虽然神经元数量、树突和突触会随着年龄增长而减少,脑室容积会增加两倍,但脑循环与年轻人相似,尽管脑血流量(CBF)有所减少。这是因为单位重量较低、CBF和脑代谢率(CMRO₂)较低,在衰老过程中它们紧密相关且自动调节功能得以保留。然而,由于多巴胺能、5-羟色胺能、胆碱能和γ-氨基丁酸能递质减少,抗胆碱能化合物(阿托品、东莨菪碱)以及一些麻醉药如氯胺酮、苯二氮䓬类甚至丙泊酚与阿片类药物合用时可能会产生谵妄和/或疗效增加。因此,在判断阿片类药物对老年人的净作用时,必须考虑与其他药物的增效和/或相加作用的药物相互作用。治疗老年患者的医生和护士往往对围手术期疼痛治疗相关并发症存在无端的恐惧。尽管已知镇痛不足可能会延迟恢复,但老年患者围手术期疼痛的治疗仍然不足,甚至相对于年轻患者也是如此。众所周知,老年人对阿片类药物的作用反应性增加。这可能会导致呼吸抑制风险增加,尤其是老年女性患者的作用持续时间会延长,但恶心风险不会增加。老年患者对全身性阿片类药物敏感性增加主要涉及药代动力学因素,如未结合和活性物质的比例较高以及药物再分布的变化。由于老年人的心输出量减少40%,阿片类药物向肝脏的再分布时间延长。这导致代谢延长,随着时间的推移失活减少,随后作用持续时间增加,主要是呼吸抑制。在较小程度上,还必须考虑在阿片受体部位反应性增加的药效学因素。尽管导致老年人阿片类药物作用差异的机制可能很复杂,但其临床意义并非如此。这些包括缓慢滴定阿片类药物以适应较长的循环时间,由于敏感性增加而降低总剂量,以及由于清除率降低而预期作用持续时间延长。由于老年患者存在多种疾病,必须根据多药联合使用情况来考虑慢性疼痛的治疗,多药联合使用由于相互作用会导致明显的副作用和作用持续时间延长。应使用那些由于其药代动力学特性而分布容积减小、血浆蛋白结合率低且最终不会形成药理活性代谢物的阿片类药物。